UA-45667900-1
Showing posts with label Lymphatic. Show all posts
Showing posts with label Lymphatic. Show all posts

Wednesday, 22 July 2026

Can restoring the brain's waste-clearance system improve brain function in Alzheimer’s and some autism?


 

One of the most exciting developments in modern neuroscience is the growing understanding of the glymphatic system—the brain's own waste-clearance system.

This network circulates cerebrospinal fluid (CSF) through the brain, removing metabolic waste products and helping maintain a healthy neuronal environment. Remarkably, the glymphatic system is most active during deep (slow-wave) sleep, suggesting that one of sleep's most important functions is to clean the brain.

Interest in this system has exploded over the past decade because impaired glymphatic function has now been implicated in Alzheimer's disease, Parkinson's disease, traumatic brain injury, stroke and several other neurological disorders.

Increasingly, researchers are also asking whether glymphatic dysfunction contributes to autism spectrum disorder (ASD).

 

A remarkably recent discovery

One of the most surprising aspects of this story is just how new it is.

The glymphatic system was only discovered in 2012 by Professor Maiken Nedergaard and colleagues. Until then, neuroscientists knew that the brain produced metabolic waste, but nobody really understood how it was removed. Unlike the rest of the body, the brain appeared to have no conventional lymphatic system.

The discovery of the glymphatic system transformed our understanding of brain biology. Researchers showed that cerebrospinal fluid flows alongside arteries into the brain, exchanges with the fluid surrounding brain cells, and then carries away waste products before leaving alongside veins.

Only three years later, in 2015, another major breakthrough followed when researchers discovered meningeal lymphatic vessels surrounding the brain. These vessels drain fluid from the glymphatic system into the body's lymphatic system.

Together, these discoveries revealed that the brain possesses its own sophisticated waste-disposal network.

Considering that this entire field is little more than a decade old, it is remarkable how quickly it has expanded. Today, impaired glymphatic function has been linked to Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, stroke, depression, schizophrenia and, increasingly, autism.

 

Autism and the glymphatic system

Until recently, the idea that glymphatic dysfunction might contribute to autism was based largely on indirect observations.

Researchers had reported:

  • enlarged extra-axial cerebrospinal fluid in some infants who later develop autism,
  • enlarged perivascular spaces,
  • chronic neuroinflammation,
  • and the very high prevalence of sleep disorders in autism.

Now, neuroimaging studies are beginning to provide more direct evidence.

A newly published MRI study examined 78 children with autism and 48 typically developing controls using the DTI-ALPS technique, a non-invasive MRI method that estimates glymphatic activity. The investigators found significantly reduced glymphatic function in the autism group. Even more interestingly, poorer glymphatic function correlated with more severe communication difficulties and poorer visual-motor integration. Statistical modelling suggested that impaired visual-motor integration partly explained the relationship between glymphatic dysfunction and communication deficits.

Glymphatic system dysfunction in children with autism spectrum disorder as evidenced by the diffusion tensor imaging along perivascular spaces index


The authors concluded that impaired glymphatic clearance may contribute to the pathophysiology of autism and represents a promising area for future mechanistic and interventional research.

These studies do not prove that impaired glymphatic clearance causes autism. However, they do suggest that it may contribute to the biology of at least a subgroup of autistic individuals.

 

Why deep sleep matters

Perhaps the most important aspect of the glymphatic system is that it works best during deep slow-wave sleep.

During deep sleep:

  • cerebrospinal fluid flows more efficiently through the brain,
  • the space between brain cells expands,
  • metabolic waste products are removed,
  • inflammatory molecules are cleared,
  • and the brain performs what is essentially its nightly housekeeping.

Sleep disturbances affect around 50–80% of autistic children, often continuing into adulthood. If glymphatic clearance depends on deep sleep, this raises the possibility that chronic sleep disruption contributes to impaired waste clearance, neuroinflammation and altered brain function, creating a vicious cycle.

This may be one reason why improving sleep often has benefits that extend well beyond simply reducing daytime fatigue.

 

Aquaporin-4: the brain's plumbing protein

The glymphatic system depends on a protein called aquaporin-4 (AQP4), which forms tiny water channels in the end-feet of astrocytes—support cells that surround the brain's blood vessels.

These channels allow cerebrospinal fluid to move efficiently between blood vessels and brain tissue, helping wash away metabolic waste products. In animal experiments, deleting AQP4 dramatically reduces glymphatic clearance, highlighting its central role in the brain's waste-disposal system.

Interestingly, several studies have reported altered AQP4 expression or localisation in autism. Although it is still unclear whether these changes are a cause or a consequence of autism, they provide another possible explanation for why glymphatic function may be impaired in at least some autistic individuals.

 

Exercise may also support the brain's cleaning system

Exercise is another intervention that may enhance glymphatic function.

Experimental studies suggest that regular physical activity can:

  • improve vascular health,
  • improve sleep quality,
  • enhance cerebrospinal fluid dynamics,
  • reduce neuroinflammation,
  • and potentially improve glymphatic clearance.

Even if future studies show only modest effects on glymphatic function, exercise already has well-established benefits for cardiovascular health, cognition, mood and healthy ageing.

 

 

 A fascinating new therapeutic idea

This brings us to one of the most intriguing studies published in the last 12 months.

The influence of intermittent hypercapnia on cerebrospinal fluid flow and clearance in Parkinson’s disease and healthy older adults


Researchers investigated whether they could artificially stimulate the glymphatic system by having volunteers breathe alternating short periods of air containing 5% carbon dioxide, followed by normal air.

Rather than continuously increasing carbon dioxide, the intermittent exposure generated rhythmic expansion and contraction of cerebral blood vessels.

Brain imaging demonstrated increased cerebrospinal fluid movement, while blood tests suggested increased movement of brain-derived proteins into the circulation, consistent with enhanced glymphatic clearance.

Importantly, this was not an autism or Alzheimer's treatment study. It was a proof-of-concept experiment involving healthy older adults and people with Parkinson's disease.

Nevertheless, it demonstrated something remarkable:

The human glymphatic system appears to be modifiable.

Mimicking what happens during deep sleep

Perhaps the most fascinating aspect of the study is the proposed mechanism.

The intermittent carbon dioxide exposure generated slow vascular oscillations remarkably similar to those naturally seen during deep sleep, when glymphatic clearance reaches its maximum.

In effect, the researchers may have temporarily reproduced one of the physiological mechanisms by which deep sleep naturally cleans the brain.

That opens an entirely new therapeutic concept.

Rather than trying to remove individual proteins such as amyloid with drugs, perhaps we can improve the brain's own housekeeping system.

 

How the intermittent CO₂ therapy was performed

The researchers did not expose participants to continuous carbon dioxide. Instead, they used a carefully controlled pattern of intermittent increase in the level of carbon dioxide (CO₂) in the blood (hypercapnia). The hypercapnia was designed to create rhythmic changes in cerebral blood flow.

Interestingly, several studies have reported abnormalities in cerebral blood flow regulation in autism, including reduced blood flow in specific brain regions and altered responses of cerebral blood vessels to changing carbon dioxide levels. Since the glymphatic system depends on rhythmic vascular pulsations to drive cerebrospinal fluid through the brain, impaired vascular regulation could potentially contribute to reduced glymphatic clearance.

Participants underwent three treatment sessions, each lasting approximately 10 minutes, for a total treatment time of about 30 minutes.

During each session they repeatedly alternated between:

  • 35 seconds breathing a gas mixture containing 5% carbon dioxide
  • 35 seconds breathing normal air

This cycle was repeated 24 times across the three sessions. The sessions were performed during a single visit, with short breaks between them.

The rationale was that the repeated dilation and relaxation of cerebral blood vessels would generate slow vascular oscillations similar to those that naturally occur during deep slow-wave sleep, when the brain's glymphatic system is most active.

MRI scans demonstrated increased cerebrospinal fluid movement through the brain, while blood tests showed increased concentrations of several brain-derived proteins—including amyloid-β, tau, GFAP and neurofilament light—in the circulation. The researchers interpreted these findings as evidence of enhanced glymphatic clearance rather than brain injury.

 

A new way of thinking

Much autism research has focused on inflammation, oxidative stress, mitochondrial dysfunction and altered neurotransmission.

But perhaps, in some autistic individuals, these abnormalities are partly downstream consequences of impaired brain waste clearance.

Instead of asking:

Which drug treats autism?

perhaps we should also ask:

Can we restore the brain's own housekeeping system?

That strategy might include:

  • protecting deep sleep
  • treating sleep disorders
  • exercising regularly
  • maintaining good cardiovascular health
  • and perhaps one day therapies that directly stimulate glymphatic flow

 

Looking ahead

This remains a hypothesis.

Neither the imaging studies nor the intermittent hypercapnia study prove that improving glymphatic function will improve autism symptoms.

However, taken together they suggest something genuinely exciting.

For the first time we now have:

  • evidence that glymphatic dysfunction is present in autism,
  • evidence that poorer glymphatic function is associated with more severe communication difficulties,
  • and evidence that the human glymphatic system may be therapeutically stimulated.

That does not yet constitute a treatment.

But it does provide the foundations for an entirely new direction of autism research—one aimed not at treating individual downstream abnormalities, but at restoring one of the brain's most fundamental maintenance systems.

If this hypothesis proves correct, the simplest interventions may remain among the most important: protect deep sleep, exercise regularly, maintain good cardiovascular health, and treat sleep disorders whenever possible. Future research will determine whether directly stimulating glymphatic flow can add to these fundamental approaches.

While a variety of therapies are marketed as improving lymphatic drainage, there is currently no convincing evidence that they enhance glymphatic clearance in humans.





Thursday, 19 October 2017

Unstable Blood Flow in Autistic Brains?





Today’s post is complicated, but may be of interest to those people interested in Nitric Oxide therapies (Agmatine, Cocoa Flavanols, Beetroot, Taurine, Citrulline etc) and those who think they are treating earlier hypoxia/ischemia.
As usual, I am making simplifications, but the science behind the general ideas already exists. When it comes to the details regarding VEGF and autism, there are big gaps in the science. 
We have already seen that something as simple as improving blood flow appears to be therapeutic in some people with autism. Perhaps there should even be a post called “cold feet and autism”. 
One reader of this blog, Seth, has commented before that he sees autism as essentially vascular in nature.  Today’s research suggests it does indeed include microvascular abnormalities.
Rather than simply reduced blood flow, the problem, in at least some autism, appears to be unstable blood flow, which is much more complex.
I do take a leap in logic to suggest that this is likely linked to the known abnormalities in Vascular Endothelial Growth Factor (VEGF) and in VEGF receptor 1 (VEGFR-1).  It also appears that the VEGF anomalies that lead to angiogenesis may be part of the reason for the increased prevalence of chronic inflammatory diseases including asthma, atopic dermatitis, psoriasis, and rheumatoid arthritis.
Ideally you might want to normalize VEGF, even later in life. The use of anti-angiogenic drugs has been suggested.  Angiogenesis inhibitors were once seen as potential wonder drugs to treat cancer.
It does seem that just simply targeting vascular resistance is helpful for some people with autism.   
VEGF is regulated by many things, some are highly complex and are usually studied with regard to cancer, like Wnt signaling and Ras. Recall that both Wnt and Ras are relevant to autism. One simple thing that influences VEGF is nitric oxide (NO), but it is not a simple relationship. As highlighted by our reader Tyler, intermittent fasting (IF) can also be used to increase VEGF. Research suggests that intermittent fasting (IF) is actually a simple but potent tool to both prevent and treat metabolic disorders, including but not limited to type 2 diabetes.


In the case of autism, where both VEGF and NO are likely to be low, it does seem quite likely that by increasing the production of NO you will increase the expression of VEGF. So the amino acid L-citrulline is likely to increase VEGF.
In the rat study below, L-citrulline increased eNOS and VEGF; we presume NO also increased. 


Blood Flow in Autistic Brains
Now we get to the autism-specific research.


A team of scientists has found evidence that people with autism have unstable vessels in the brain which prevents the proper delivery of blood flow, according to research published in the Journal of Autism and Developmental Disorders
“In a typical brain, blood vessels are stable, thereby ensuring a stable distribution of blood,” said Patricia Whitaker-Azmitia, PhD, professor in the Department of Psychology and director of the Graduate Program in Integrative Neurosciences at Stony Brook University, N.Y.,  in a statement. “Whereas in the autism brain, the cellular structure of blood vessels continually fluctuates, which results in circulation that is fluctuating and, ultimately, neurologically limiting.”



Sustained angiogenesis may contribute to prolonged neuroplasticity in the ASD brain. We propose the sustained splitting angiogenesis is a necessary component to maintain the heightened neuronal activity reported in ASD patients. Many biological and functional indicators are increased in ASD including cerebral metabolic rate, regional synchronous electrical activity sensitivity to sound; cortical activity in deactivation centers at rest, low-level visuospatial processing, visual-tactile interactions; attention to low-level perceptual information and over-connected, redundant cortical networks. It can be suggested that sustained rearrangement of microvasculature permits excessive shorter and local connections to be maintained and prevents the growth of longer and more complex brain connections required for language and social interactions. Use of anti-angiogenic drugs may provide a novel treatment strategy for reducing neuronal activity in ASD patients by inhibiting vascular plasticity.








Brain tissue from children (left) and adults (right) with autism (top) but not controls (bottom) shows dividing cells lining blood vessels.


Angiogenesis and Lymphangiogenesis
It looks like, at least in today’s subgroup of autism, we want less angiogenesis but more lymphangiogenesis.  The ideal way to do this is via VEGF/VEGFRs.
Here it may be helpful to explain the meaning of some new terminology.

Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels
Angiogenesis is a normal and vital process in growth and development, as well as in wound healing and in the formation of granulation tissue. However, it is also a fundamental step in the transition of tumors from a benign state to a malignant one, leading to the use of angiogenesis inhibitors in the treatment of cancer.”
Lymphangiogenesis is the formation of lymphatic vessels from pre-existing lymphatic vessels in a method believed to be similar to angiogenesis (blood vessel development).

Lymphangiogenesis plays an important physiological role in homeostasis, metabolism and immunity. Impaired or excessive lymphatic vessel formation has been implicated in a number of pathological conditions including neoplasm metastasis, oedema, rheumatoid arthritis, psoriasis, lymphangiomatosis and impaired wound healing.”


Lymphatic system and the Brain 
As highlighted recently by our reader Tanya, a pretty basic gap in science’s understanding of how the brain works has just been addressed. It is all about where do the waste products produced in the brain go to.
Scientists have found evidence that the brain is connected to body’s central lymphatic system.
This then begs the question of what happens when this system does not work well. Is this a feature of some neurological disease? If that were the case, it would likely be associated with reduced lymphangiogenesis.

Running through your body is a network of channels and junctions called the lymphatic system, which siphons off waste and fluids like a biological sewer.
It was long thought the brain was excluded from this web of anatomical plumbing. After being spotted in mice brains two years ago, researchers have now confirmed the presence of lymphatic vessels in human brains, fueling speculation over the kinds of diseases they might be responsible for.




VEGF and VEGF receptors 
There are four types of VEGF and they act through three types of receptors. Confusingly, the receptors have been given multiple names.


In severe autism there is reduced VEGF, but we do not know which type(s) but there is increased expression of the receptor  VEGFR-1 also known as Flt-1. VEGFR-2 expression is normal, this is the best understood receptor.

This receptor VEGFR-1 is activated by VEGF-A and VEGF-B.  

Objective:

To study vascular endothelial growth factor (VEGF) and its soluble receptors sVEGFR-1 and -2 in autism.

Design and methods:

We measured serum levels of angiogenic molecules in 22 patients with severe autism and 28 controls.

Results:

Patients and controls had similar sVEGFR-2 levels, but VEGF levels were lower and sVEGFR-1 higher in patients with autism.

Conclusion:

The imbalance between VEGF and its receptor sVEGFR-1 may be involved in the pathophysiology of autism.


Hypoxia related autism 
It is well known that hypoxia-ischemia insults early in life can cause cognitive dysfunction and likely autism.  In the very recent paper below, it is suggested that altered VEGF signaling is the mechanism that causes the damage to the brain. 

Neurovascular dysfunction and the role of vascular endothelial growth factor (VEGF) have been explored in neurodevelopmental disorders including schizophrenia, bipolar disorder, major depressive and mood disorders, and autism. These disorders are correlated with hypoxia-ischemia insults during early life and are strongly associated with cognitive dysfunction. This review focuses on the hypoxia-regulated protein, VEGF, to discuss its crucial roles in brain development and function. These data implicate that alterations to VEGF signaling during early life can impair neural development, underlying the severe cognitive deficits observed in neurodevelopmental disorders.
Recent Findings
VEGF has been linked to neurological processes that influence learning and memory. VEGF is advancing towards being a novel biomarker and possible therapeutic for neurological disorders. Prenatal environmental enrichment positively impacted neurotrophic factors, brain structure, and memory in rodent models.
Summary
Understanding the molecular mechanisms of VEGF in neurodevelopment will create intervention strategies for at-risk children born to adverse early-life events. By proactively working with those in a pliable neurodevelopmental state, we hope to ameliorate cognitive deficits to increase their chance to develop into high-functioning adults with disabilities. 

Hypoxia-Induced Angiogenesis - Good and Evil


Hypoxia promotes vessel growth by upregulating multiple pro-angiogenic pathways that mediate key aspects of endothelial, stromal, and vascular support cell biology. Interestingly, recent studies show that hypoxia influences additional aspects of angiogenesis, including vessel patterning, maturation, and function.
VEGF, considered a master regulator of angiogenesis in its own right, causes endothelial cells to detach from the parent vessel and migrate into the neighboring stroma. Hypoxia is the principal regulator of VEGF expression, as it is a direct transcriptional target of both HIF-1α and HIF-2α.



Allergy and inflammation resulting from angiogenesis 
It appears that in some people another consequence of too much angiogenesis is allergy and other inflammatory disease; these are of course often comorbid with autism.  This suggests anti-angiogenic and pro-lymphangiogenic therapies.


Angiogenesis and lymphangiogenesis, the growth of new vessels from preexisting ones, have received increasing interest due to their role in tumor growth and metastatic spread. However, vascular remodeling, associated with vascular hyperpermeability, is also a key feature of many chronic inflammatory diseases including asthma, atopic dermatitis, psoriasis, and rheumatoid arthritis. The major drivers of angiogenesis and lymphangiogenesis are vascular endothelial growth factor- (VEGF-)A and VEGF-C, activating specific VEGF receptors on the lymphatic and blood vascular endothelium. Recent experimental studies found potent anti-inflammatory responses after targeted inhibition of activated blood vessels in models of chronic inflammatory diseases. Importantly, our recent results indicate that specific activation of lymphatic vessels reduces both acute and chronic skin inflammation. Thus, antiangiogenic and prolymphangiogenic therapies might represent a new approach to treat chronic inflammatory disorders, including those due to chronic allergic inflammation.



Figure 1: VEGF-binding properties and distinct VEGF receptor expression on lymphatic and blood vascular endothelium. VEGFs bind to the three VEGF receptor tyrosine kinases, leading to the formation of VEGFR dimers. Blood vascular endothelial cells express VEGFR-1 and VEGFR-2, whereas lymphatic endothelial cells express VEGFR-2 and VEGFR-3. VEGF-A—which binds both VEGFR-1 and VEGFR-2—can directly induce blood and lymphatic vascular remodeling. VEGF-C and -D bind VEGFR-3 and, after proteolytic processing, also VEGFR-2, thus inducing angiogenesis and lymphangiogenesis.


There is clear evidence that in humans, vascular remodeling occurs in many chronic inflammatory disorders. Even though different anti-inflammatory drugs are on the market, there is no specific therapy that interferes with the pathological vascular changes that occur during inflammation. Angiogenesis and lymphangiogenesis are tightly linked to chronic inflammation, and targeting the blood vessels and lymphatic vessels has been shown to be an effective strategy in different experimental mouse models of chronic inflammation. One has to keep in mind, however, that in most conditions the vascular activation likely represents a downstream event that maintains the inflammatory process, but not the pathogenetic cause of the respective disease, which often has remained unknown. Nonetheless, antiangiogenic and prolymphangiogenic therapies might represent new approaches to treat chronic inflammatory disorders, including those due to chronic allergic inflammation.


Conclusion
I did start this post by saying this subject is complicated.
From the previous post on nitric oxide, it looked like L-citrulline, L-norvaline, Agmatine and other NO increasing substances could be therapeutic. Cold hands and feet seem to be very common in autism.
It seems likely that the NO increasing therapies will likely also increase VEGF, which I think is a good thing.
From today’s post we see that rather than just a single VEGF we have five broad types (A,B,C, D and PIGF), but even just VEGF-A has various different forms. We do not have detailed research on autism and specific subtypes of VEGF. 
We have the four different VEGF receptors and we know VEGFR-1 is over expressed. We do not have a clever way to counter this. More VEGFR-3 expression would be helpful and that is again a case of changing the balance between inflammatory cytokines, which as we know is usually disturbed in autism.
The inflammatory cytokine IL-6 induces VEGF-C production which leads to both angiogenesis and lymphangiogenesis; this is why people with cancer and high IL-6 may have a poor prognosis.
Regarding VEGF and autism we clearly lack 95% of the science. Strange things are afoot and we are just guessing.
For the time being, I see increasing vascular permeability via eNOS as therapeutic, even though today’s post suggests that antiangiogenic therapies could be helpful, which may seem contradictory.
The kind of drugs that would reduce the activity of VEGFR-1/Flt-1 would be very expensive cancer drugs.  Hypoxia also downregulates VEGFR-1/Flt-1.
Inflammatory cytokines regulate VEGFR-3/Flt-4 and hence control of lymphangiogenesis.  Interferon gamma (IFNγ) upregulates VEGFR-3/Flt-4, while Interleukin 1 beta (IL1β) down regulates it. 
So more IFNγ and less IL1β might help.
Although expensive, interferon gamma (IFNγ) has been shown to be effective in treating severe atopic dermatitis. This would make sense since it induces lymphangiogenesis and the research suggests this should improve inflammatory disease.


CONCLUSIONS:


We conclude that rIFN-gamma appears to be a safe long-term therapy for patients with severe atopic dermatitis.



So perhaps interferon-gamma (IFNγ) for some autism? Quite possibly, just look for the ones with asthma, atopic dermatitis, psoriasis or juvenile arthritis.